FTC Lawsuit Targets Hims & Hers Business Practices, Impacting Stock
Hims & Hers (HIMS) stock dropped significantly following a lawsuit filed by the Federal Trade Commission along with Utah and Los Angeles County. The suit accuses the telehealth provider of misleading consumers regarding recurring subscriptions, obstructing cancellations, and illegally sharing patient health data with ad platforms like Meta (META) and Snap (SNAP). While shares rebounded slightly on July 30, they remain down about 32% from their recent high. The lawsuit is seen as a major blow to HIMS' direct-to-consumer business model. The allegations could lead to financial penalties, increased churn rates, higher customer acquisition costs, and loss of consumer trust—critical for telehealth platforms. Analysts suggest the stock's drop below its 100-day moving average indicates potential bearish momentum. Despite recent volatility, Wall Street analysts maintain a 'Hold' rating on HIMS with an average price target suggesting about 20% upside from current levels.
Topics: data privacy FTC lawsuit stock impact telehealth regulation